{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T18:39:53Z","timestamp":1767206393596,"version":"build-2238731810"},"reference-count":40,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2016,10,2]],"date-time":"2016-10-02T00:00:00Z","timestamp":1475366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["JCM"],"abstract":"<jats:p>In the congestive heart failure (CHF) setting, chronic hyponatremia is very common. The present review aims at addressing topics relevant to the pathophysiology of hyponatremia in the course of CHF as well as its optimal treatment, including the main advantages and the limitations resulting from the use of the available dietary and pharmacological measures approved for the treatment of this electrolytic trouble. A narrative review is carried out in order to represent the main modalities of therapy for chronic hyponatremia that frequently complicates CHF. The limits of usual therapies implemented for CHF-related chronic hyponatremia are outlined, while an original analysis of the main advancements achieved with the use of vasopressin receptor antagonists (VRAs) is also executed. The European regulatory restrictions that currently limit the use of VRAs in the management of CHF are substantially caused by financial concerns, i.e., the high costs of VRA therapy. A thoughtful reworking of current restrictions would be warranted in order to enable VRAs to be usefully associated to loop diuretics for decongestive treatment of CHF patients with hyponatremia.<\/jats:p>","DOI":"10.3390\/jcm5100086","type":"journal-article","created":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T10:17:01Z","timestamp":1475489821000},"page":"86","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["RETRACTED: Vasopressin Receptor Antagonists for the Correction of Hyponatremia in Chronic Heart Failure: An Underutilized Therapeutic Option in Current Clinical Practice?"],"prefix":"10.3390","volume":"5","author":[{"given":"Renato","family":"De Vecchis","sequence":"first","affiliation":[{"name":"Cardiology Unit, Presidio Sanitario Intermedio \u201cElena d\u2019Aosta\u201d, ASL Napoli 1 Centro, via Cagnazzi 29, 80137 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Cantatrione","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Presidio Sanitario Intermedio \u201cElena d\u2019Aosta\u201d, ASL Napoli 1 Centro, via Cagnazzi 29, 80137 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damiana","family":"Mazzei","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Presidio Sanitario Intermedio \u201cElena d\u2019Aosta\u201d, ASL Napoli 1 Centro, via Cagnazzi 29, 80137 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesare","family":"Baldi","sequence":"additional","affiliation":[{"name":"Heart Department, Interventional Cardiology, Azienda Ospedaliero-Universitaria \u201cSan Giovanni di Dio e Ruggi d\u2019Aragona\u201d, via San Leonardo 1, 84131 Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,10,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"882","DOI":"10.4158\/EP10154.RA","article-title":"Hyponatremia: Mechanisms and newer treatments","volume":"16","author":"Zeidel","year":"2010","journal-title":"Endocr. Pract."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7326\/0003-4819-113-2-155","article-title":"Body fluid volume regulation in health and disease: A unifying hypothesis","volume":"113","author":"Schrier","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1681\/ASN.2006111302","article-title":"Decreased effective blood volume in edematous disorders: What does this mean?","volume":"18","author":"Schrier","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/eurjhf\/hfq104","article-title":"Loop diuretic therapy in left ventricular systolic dysfunction: Has familiarity bred contempt for a critical but potentially nephrotoxic cardio renal therapy?","volume":"12","author":"MacFadyen","year":"2010","journal-title":"Eur. J. Heart Fail."},{"key":"ref_5","first-page":"571","article-title":"Unloading therapy by intravenous diuretic in chronic heart failure: A double-edged weapon?","volume":"11","author":"Ciccarelli","year":"2010","journal-title":"J. Cardiovasc. Med."},{"key":"ref_6","first-page":"251","article-title":"Hypertonic saline solution for renal failure prevention in patients with decompensated heart failure","volume":"89","author":"Issa","year":"2007","journal-title":"Arq. Bras. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2459\/JCM.0b013e3283376bfa","article-title":"Diuretic therapy in heart failure: Current controversies and new approaches for fluid removal","volume":"11","author":"Brandimarte","year":"2010","journal-title":"J. Cardiovasc. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/0002-9149(83)90200-X","article-title":"Association of hyponatremia with increased renin activity in chronic congestive heart failure: Impact of diuretic therapy","volume":"51","author":"Schaer","year":"1983","journal-title":"Am. J. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1388-9842(02)00097-1","article-title":"Serum to urinary sodium concentration ratio is an estimate of plasma renin activity in congestive heart failure","volume":"4","author":"Marenzi","year":"2002","journal-title":"Eur. J. Heart Fail"},{"key":"ref_10","first-page":"1273","article-title":"Recent advances in the investigation of the renin-angiotensin and cardiac natriuretic systems in patients with chronic heart insufficiency","volume":"84","author":"Arnal","year":"1991","journal-title":"Arch. Mal Coeur Vaiss."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1078-0432.CCR-05-1536","article-title":"A metabolic study of patients with lung cancer and hyponatremia of malignancy","volume":"12","author":"Chute","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2009.05.015","article-title":"The occurrence of hyponatremia in SCLC and the influence on prognosis: A retrospective study of 453 patients treated in a single institution in a 10-year period","volume":"68","author":"Hansen","year":"2010","journal-title":"Lung Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"754","DOI":"10.2459\/JCM.0b013e328011c256","article-title":"Relative adrenal insufficiency in severe congestive heart failure with preserved systolic function: A case report","volume":"8","author":"Lovelock","year":"2007","journal-title":"J. Cardiovasc. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1210\/jc.2006-0674","article-title":"Hypothalamic pituitary adrenal function during critical illness: Limitations of current assessment methods","volume":"91","author":"Arafah","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.7326\/0003-4819-110-1-24","article-title":"Thiazide-induced hyponatremia. Reproducibility by single dose rechallenge and an analysis of pathogenesis","volume":"110","author":"Friedman","year":"1989","journal-title":"Ann. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/ndt\/15.12.1903","article-title":"New insights into the paradoxical effect of thiazides in diabetes insipidus therapy","volume":"15","author":"Magaldi","year":"2000","journal-title":"Nephrol. Dial Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00005792-197905000-00004","article-title":"The syndrome of inappropriate antidiuretic hormone secretion (SIADH): Pathophysiologic mechanisms in solute and volume regulation","volume":"58","author":"Cooke","year":"1979","journal-title":"Medicine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000047939","article-title":"Central pontine myelinolysis","volume":"47","author":"Lampl","year":"2002","journal-title":"Eur. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/j.jacc.2005.01.059","article-title":"Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: A double-blind study","volume":"45","author":"Paterna","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00059-013-4041-6","article-title":"Hypertonic saline plus i.v. furosemide improve renal safety profile and clinical outcomes in acute decompensated heart failure: A meta-analysis of the literature","volume":"40","author":"Esposito","year":"2015","journal-title":"Herz"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Efficacy of vasopressin antagonism in heart failure outcome study with Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1253\/circj.CJ-14-0126","article-title":"Efficacy and safety of tolvaptan in heart failure patients with volume overload","volume":"78","author":"Kinugawa","year":"2014","journal-title":"Circ. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1536\/ihj.14-332","article-title":"Effectiveness and adverse events of tolvaptan in octogenarians with heart failure. Interim analyses of Samsca Post-Marketing Surveillance in Heart Failure (SMILE study)","volume":"56","author":"Kinugawa","year":"2015","journal-title":"Int. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijcard.2016.07.063","article-title":"Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction","volume":"221","author":"Matsue","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00228-016-2091-4","article-title":"Risk factors for hypernatremia in patients with short- and long-term tolvaptan treatment","volume":"72","author":"Hirai","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hanatani, A., Shibata, A., Kitada, R., Iwata, S., Matsumura, Y., Doi, A., Sugioka, K., Takagi, M., and Yoshiyama, M. (2016). Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction. Heart Vessels.","DOI":"10.1007\/s00380-016-0872-4"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/jc.2012-4082","article-title":"Clinical review: The use of vaptans in clinical endocrinology","volume":"98","author":"Peri","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/ki.2012.402","article-title":"Where vaptans do and do not fit in the treatment of hyponatremia","volume":"83","author":"Jovanovich","year":"2013","journal-title":"Kidney Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s11897-010-0035-3","article-title":"Targeting hyponatremia and hemodynamics in acute decompensated heart failure: Is there a role for vasopressin antagonists?","volume":"8","author":"Valania","year":"2011","journal-title":"Curr. Heart Fail Rep."},{"key":"ref_31","first-page":"517","article-title":"In right or biventricular chronic heart failure addition of thiazides to loop diuretics to achieve a sequential blockade of the nephron is associated with increased risk of dilutional hyponatremia: Results of a case-control study","volume":"60","author":"Ariano","year":"2012","journal-title":"Minerva Cardioangiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/eurheartj\/ehi845","article-title":"Italian survey on Acute Heart Failure Investigators. Nationwide survey on acute heart failure in cardiology ward services in Italy","volume":"27","author":"Tavazzi","year":"2006","journal-title":"Eur. Heart J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/eurheartj\/ehl542","article-title":"OPTIMIZE-HF Investigators and Coordinators. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: An analysis from the OPTIMIZE-HF registry","volume":"28","author":"Gheorghiade","year":"2007","journal-title":"Eur. Heart J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2459\/JCM.0b013e32834ae87e","article-title":"IN-CHF Investigators. Relation between serum sodium levels and prognosis in outpatients with chronic heart failure: Neutral effect of treatment with beta-blockers and angiotensin-converting enzyme inhibitors: Data from the Italian Network on Congestive Heart Failure (IN-CHF database)","volume":"12","author":"Baldasseroni","year":"2011","journal-title":"J. Cardiovasc. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4330\/wjc.v5.i9.317","article-title":"Hyponatremia in patients with heart failure","volume":"5","author":"Filippatos","year":"2013","journal-title":"World J. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.clinthera.2010.06.015","article-title":"Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: A clinical review","volume":"32","author":"Nemerovski","year":"2010","journal-title":"Clin. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.cardfail.2011.08.012","article-title":"Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure","volume":"17","author":"Goldsmith","year":"2011","journal-title":"J. Card. Fail"},{"key":"ref_38","first-page":"693","article-title":"Awareness and management of hyponatraemia: The Italian Hyponatraemia Survey","volume":"36","author":"Giuliani","year":"2013","journal-title":"J. Endocrinol. Investig."},{"key":"ref_39","first-page":"559","article-title":"Hyponatremia now\u2014A goldmine or a dead end?","volume":"21","author":"Gross","year":"2012","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrneph.2012.246","article-title":"Hyponatraemia: More than just a marker of disease severity?","volume":"9","author":"Schrier","year":"2013","journal-title":"Nat. Rev. Nephrol."}],"updated-by":[{"DOI":"10.3390\/jcm13061743","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"record-id":"52923"},{"DOI":"10.3390\/jcm13061743","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2016,10,2]],"date-time":"2016-10-02T00:00:00Z","timestamp":1475366400000}}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/5\/10\/86\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T23:37:26Z","timestamp":1754264246000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/5\/10\/86"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,2]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,10]]}},"alternative-id":["jcm5100086"],"URL":"https:\/\/doi.org\/10.3390\/jcm5100086","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,2]]}}}